Piper Sandler analyst Allison Bratzel downgraded enGene (ENGN) to Neutral from Overweight with a price target of $4, down from $7, after the company announced interim results from the pivotal cohort of LEGEND, evaluating detalimogene in BCG-unresponsive non-muscle invasive bladder cancer. Piper says it “cannot get comfortable” that detalimogene will have a competitive profile when complete data is available in the second half of 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
- enGene downgraded to Market Perform from Outperform at Citizens
- enGene downgraded to Equal Weight from Overweight at Wells Fargo
- enGene downgraded to Equal Weight from Overweight at Morgan Stanley
- enGene downgraded to Neutral from Buy at Guggenheim
- enGene announces updated interim results from LEGEND cohort